Toxicity of Olaratumab and Doxorubicin

ANNOUNCE: Combination of olaratumab and doxorubicin versus doxorubicin alone in patients with ad...Подробнее

Dr. Robin Jones on Olaratumab and Doxorubicin in Patients with Soft Tissue SarcomaПодробнее

Dr. Tap on Improved Overall Survival With Olaratumab/Doxorubicin CombinationПодробнее

Registration Trials for Olaratumab and Doxorubicin for STSПодробнее

Olaratumab Plus Doxorubicin in Advanced Soft Tissue SarcomaПодробнее

Dr. Pautier on Doxorubicin Plus Trabectedin in Soft Tissue SarcomaПодробнее

ANNOUNCE: doxorubicin + olaratumab in advanced soft tissue sarcomasПодробнее

Appropriate Patients for Olaratumab + DoxorubicinПодробнее

Olaratumab + Doxorubicin for Metastatic Soft-Tissue SarcomaПодробнее

Overall Survival with OlaratumabПодробнее

Cardiac protection of B307 in doxorubicin-treated mice - Video abstract [ID 82936]Подробнее

Overall Survival with OlaratumabПодробнее

Olaratumab for LMSПодробнее

FDA Approval of Olaratumab + Doxorubicin for STSПодробнее

Cardiotoxicity: Treatment & DiagnosisПодробнее

Chemotherapy Toxicity Considerations in Soft Tissue SarcomaПодробнее

Soft Tissue Sarcoma: Role of OlaratumabПодробнее

CTOS Rome STS Lecture 2 Phase 1B Study of Olaratumab plus Doxorubicin and Ifosfamide in Patients wПодробнее

Olaratumab for LMSПодробнее